SCM
CTMX icon

Soleus Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Soleus Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-300,000
Closed -$1.41M – 101
2026
Q1 		$1.41M Buy
+300,000
New +$1.52M 0.06% 80
2025
Q3 		– Sell
-1,304,300
Closed -$2.96M – 94
2025
Q2 		$2.96M Buy
+1,304,300
New +$2.1M 0.2% 69
2021
Q4 		– Sell
-261,050
Closed -$1.33M – 76
2021
Q3 		$1.33M Buy
+261,050
New +$1.4M 0.21% 63

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Soleus Capital Management's CTMX Position: Q2 2026 in Review

Soleus Capital Management sold out of CytomX Therapeutics (CTMX) in Q2 2026, closing a stake of 300,000 shares — an estimated $1.41M sold.

Soleus Capital Management first reported a position in CTMX in Q3 2021 and held it in 3 quarters. The position peaked at $2.96M in Q2 2025. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Soleus Capital Management reported no remaining CytomX Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Soleus Capital Management sold 300,000 CytomX Therapeutics shares in Q2 2026, an estimated $1.41M.
  • Soleus Capital Management first reported a position in CytomX Therapeutics in Q3 2021 and held it in 3 quarters.
  • Soleus Capital Management's CytomX Therapeutics position peaked at $2.96M in Q2 2025.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.